Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivos Therapeutics ( (VVOS) ) has provided an announcement.
On December 5, 2025, Vivos Therapeutics, Inc. entered into a Note Purchase Agreement with Avondale Capital, LLC, resulting in a $2,093,340 promissory note. The company received approximately $1,500,000 in net proceeds, which it intends to use for working capital and general corporate purposes. The note, which is unsecured and non-convertible, includes an original issue discount and requires weekly payments. Vivos Therapeutics has also arranged for its subsidiary to guarantee the company’s obligations under the note. The agreement outlines customary events of default, such as nonpayment and bankruptcy, which could trigger interest accrual or immediate repayment.
The most recent analyst rating on (VVOS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
Vivos Therapeutics’ overall score is driven by strong revenue growth and strategic business model shifts, as highlighted in the earnings call. However, financial performance struggles, bearish technical indicators, and poor valuation metrics weigh heavily on the score.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc. operates in the healthcare industry, focusing on therapeutic solutions. The company is involved in providing innovative treatments and services, with a market focus on improving patient outcomes.
Average Trading Volume: 278,135
Technical Sentiment Signal: Sell
Current Market Cap: $19.32M
See more data about VVOS stock on TipRanks’ Stock Analysis page.